Inclusion Criteria for Cohort 1:  HIV-positive English or Spanish speaking Lab values that indicate the patient is a candidate for the medication and virally suppressed Willing to complete the locator form to receive appointment reminders prior to follow-up data collection  Inclusion Criteria for Cohort 2:  HIV-positive English or Spanish speaking Enrolled in care and receiving CAB-RPV LA injection at Boston Medical Center Infectious Disease Clinic (HIV clinic) Willing to complete the locator form to receive appointment reminders prior to follow-up data collection  Inclusion Criteria for Cohort 3:  HIV-positive English or Spanish speaking Enrolled in care but NOT receiving CAB-RPV LA injection at Boston Medical Center Infectious Disease Clinic (HIV clinic) Willing to complete the locator form to receive appointment reminders prior to follow-up data collection Matched to participants demographically and in terms of other characteristics in Cohort 1 at a 2:1 ratio  Exclusion Criteria (for all 3 cohorts unless stated):  Not virally suppressed prior to beginning CAB-RPV LA (does not apply to cohort 3) A history of adhering fully to their antiretroviral therapy (ART) Not willing to take CAB-RPV LA after detailed discussion of what the use of CAB-RPV LA will entail (does not apply to cohort 3) Unable to undergo clinical eligibility testing to confirm eligibility (does not apply to cohort 3) A history of integrase inhibitor mutations suggesting resistance to Cabotegravir or Cabenuva A history or evidence of resistance to either integrase strand transfer inhibitor (INSTI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) HIV drugs Currently pregnant or breastfeeding Currently has HIV 1 with an HIV 2 co-infection or an HIV 2 infection Taking any drugs that have known interactions with Cabenuva, including but not limited to carbamazepine, oxcarbazepine, phenobarbital, phenytoin, St Johns Wort, systemic Dexamethasone, rifabutin, rifampin and rifapentine Chronic Hepatitis B infection